Hi-Tech Pharmacal Ups R&D Spending At Expense Of Earnings
This article was originally published in The Tan Sheet
Executive Summary
Hi-Tech Pharmacal nearly doubled its research and development spending in its second fiscal quarter as the firm worked on Rx and OTC generic versions of a number of branded drug products